{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:52:53Z","timestamp":1790949173889,"version":"4.1.0"},"reference-count":27,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0232473","type":"journal-article","created":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T17:25:29Z","timestamp":1588353929000},"page":"e0232473","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":11,"title":["\u201cIt made me more confident that I have it under control\u201d: Patient and provider\u00a0perspectives on moving to a two-drug ART regimen in the United States and Spain"],"prefix":"10.1371","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4521-0688","authenticated-orcid":true,"given":"Wendy","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mantsios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahilin","family":"Karver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Murray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yogesh","family":"Punekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Ward","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U. Fritz","family":"Bredeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Moreno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dolores","family":"Merino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernando","family":"Knobel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Campis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deanna","family":"Kerrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2020,5,1]]},"reference":[{"issue":"3","key":"pone.0232473.ref001","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1097\/COH.0b013e328329fc8d","article-title":"Improvements in antiretroviral therapy outcomes over calendar time","volume":"4","author":"MA Boyd","year":"2009","journal-title":"Curr Opin HIV AIDS"},{"issue":"9635","key":"pone.0232473.ref002","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/S0140-6736(08)61113-7","article-title":"Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies","volume":"372","author":"The Antiretroviral Therapy Cohort Collaboration","year":"2008","journal-title":"Lancet"},{"issue":"4","key":"pone.0232473.ref003","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1001\/jama.2012.7961","article-title":"Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel","volume":"308","author":"MA Thompson","year":"2012","journal-title":"JAMA"},{"issue":"16","key":"pone.0232473.ref004","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.2165\/11640830-000000000-00000","article-title":"NRTI backbone in HIV treatment","volume":"72","author":"R Tressler","year":"2012","journal-title":"Drugs"},{"issue":"1","key":"pone.0232473.ref005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s13181-013-0325-8","article-title":"A review of the toxicity of HIV Medications","volume":"10","author":"AM Margolis","year":"2014","journal-title":"Journal of Medical Toxicology"},{"key":"pone.0232473.ref006","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with HIV-1 infection (FLAMINGO): 48 week results from the randomised open-label phase 3 study","volume":"383","author":"B Clotet","year":"2014","journal-title":"Lancet"},{"key":"pone.0232473.ref007","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1056\/NEJMoa1215541","article-title":"Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection","volume":"369","author":"SL Walmsley","year":"2013","journal-title":"N Engl J Med"},{"key":"pone.0232473.ref008","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/infdis\/jiu051","article-title":"Dolutegravir in antiretroviral-experienced patients with raltegravir- and\/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study","volume":"210","author":"A Castagna","year":"2014","journal-title":"J Infect Dis"},{"issue":"3","key":"pone.0232473.ref009","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s40121-015-0071-0","article-title":"Cost effectiveness of dolutegravir in HIV-1 treatment-aive and treatment-experienced patients in Canada","volume":"4","author":"N Despi\u00e9gel","year":"2015","journal-title":"Infect Dis Ther"},{"key":"pone.0232473.ref010","unstructured":"SWORD-1. (June 6, 2017) Regimen switch to dolutegravir + rilpivirine from current antiretroviral regimen in Human Immunodeficiency Virus Type 1 infected and virologically suppressed adults; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02429791."},{"key":"pone.0232473.ref011","unstructured":"SWORD-2. (June 6, 2017) Regimen switch to dolutegravir + rilpivirine from current antiretroviral regimen in Human Immunodeficiency Virus Type 1 infected and virologically suppressed adults; Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02422797."},{"issue":"10123","key":"pone.0232473.ref012","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","article-title":"Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies","volume":"391","author":"J Llibre","year":"2018","journal-title":"Lancet"},{"issue":"10167","key":"pone.0232473.ref013","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"P Cahn","year":"2018","journal-title":"Lancet"},{"issue":"8","key":"pone.0232473.ref014","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1177\/1060028019831674","article-title":"Dolutegravir-rilpivirine, dual antiretroviral therapy for the treatment of HIV-1 infection","volume":"53","author":"EK Hester","year":"2019","journal-title":"Ann Pharmacother"},{"issue":"1","key":"pone.0232473.ref015","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1177\/1525822X05279903","article-title":"How many interviews are enough?: an experiment with data saturation and variability","volume":"18","author":"G Guest","year":"2006","journal-title":"Field Methods"},{"key":"pone.0232473.ref016","volume-title":"Qualitative research and evaluation methods","author":"MQ Patton","year":"2001"},{"issue":"7227","key":"pone.0232473.ref017","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/bmj.320.7227.114","article-title":"Analysing qualitative data","volume":"320","author":"C Pope","year":"2000","journal-title":"BMJ"},{"key":"pone.0232473.ref018","unstructured":"Scientific Software Development.(2013) GmbH, ATLAS.ti: Eden Prairie, MN."},{"issue":"11","key":"pone.0232473.ref019","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1089\/apc.2018.0094","article-title":"Barriers and facilitators to seeking HIV services in Chicago among young men who have sex with men: Perspectives of HIV service providers","volume":"32","author":"LB Beach","year":"2018","journal-title":"AIDS Patient Care STDS"},{"issue":"5","key":"pone.0232473.ref020","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1089\/apc.2018.0018","article-title":"Barriers and facilitators for clinical care engagement among HIV-positive African American and Latino Men who have sex with men","volume":"32","author":"JW Carey","year":"2018","journal-title":"AIDS Patient Care STDS"},{"issue":"1","key":"pone.0232473.ref021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1521\/aeap.2018.30.1.1","article-title":"Willingness to take PrEP for HIV prevention: The combined effects of race\/ethnicity and provider trust","volume":"30","author":"A Braksmajer","year":"2018","journal-title":"AIDS Educ Prev"},{"key":"pone.0232473.ref022","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.curtheres.2015.08.002","article-title":"Pill properties that cause dysphagia and treatment failure","volume":"77","author":"J Fields","year":"2015","journal-title":"Curr Ther Res Clin Exp"},{"issue":"11","key":"pone.0232473.ref023","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1007\/s10461-018-2102-9","article-title":"Barriers and facilitators to oral PrEP use among transgender women in New York City","volume":"22","author":"CT Rael","year":"2018","journal-title":"AIDS Behav"},{"key":"pone.0232473.ref024","first-page":"1","article-title":"Understanding HIV-related pill aversion as a distinct barrier to medication adherence","volume":"3","author":"RM Dorman","year":"2019","journal-title":"Behav Med"},{"issue":"8","key":"pone.0232473.ref025","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1097\/QAD.0000000000001068","article-title":"Socioeconomic status and response to antiretroviral therapy in high-income countries: a literature review","volume":"30","author":"L Burch","year":"2016","journal-title":"AIDS"},{"key":"pone.0232473.ref026","article-title":"Is DTG+3TC and DTG+RPV effective and safe in clinical practice? Evidence from real world data","author":"YS Punekar","year":"2019","journal-title":"International AIDS Society"},{"issue":"12","key":"pone.0232473.ref027","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1097\/QAD.0000000000001845","article-title":"The transition to dolutegravir and other new antiretrovirals in low-income and middle-income countries: what are the issues?","volume":"32","author":"M Vitoria","year":"2018","journal-title":"AIDS"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0232473","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T17:25:51Z","timestamp":1588353951000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0232473"}},"subtitle":[],"editor":[{"given":"Webster","family":"Mavhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2020,5,1]]},"references-count":27,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5,1]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0232473","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,1]]}}}